Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cornea | 33 | 2025 | 81 | 4.560 |
Why?
|
| Keratoconus | 16 | 2025 | 18 | 3.680 |
Why?
|
| Corneal Topography | 25 | 2025 | 32 | 2.910 |
Why?
|
| Myopia | 14 | 2023 | 29 | 2.340 |
Why?
|
| Refractive Errors | 13 | 2022 | 30 | 2.200 |
Why?
|
| Down Syndrome | 9 | 2022 | 31 | 2.040 |
Why?
|
| Visual Acuity | 21 | 2023 | 117 | 2.030 |
Why?
|
| Vision Screening | 6 | 2022 | 21 | 1.690 |
Why?
|
| Vision Disorders | 5 | 2020 | 61 | 1.220 |
Why?
|
| Anterior Chamber | 5 | 2020 | 14 | 1.140 |
Why?
|
| Lasers, Excimer | 6 | 2023 | 7 | 1.130 |
Why?
|
| Photorefractive Keratectomy | 5 | 2023 | 6 | 1.110 |
Why?
|
| Refraction, Ocular | 17 | 2023 | 66 | 1.030 |
Why?
|
| Photochemotherapy | 6 | 2023 | 42 | 0.930 |
Why?
|
| Lens Implantation, Intraocular | 3 | 2015 | 27 | 0.880 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2025 | 89 | 0.870 |
Why?
|
| Phacoemulsification | 3 | 2015 | 28 | 0.860 |
Why?
|
| Iran | 26 | 2022 | 199 | 0.860 |
Why?
|
| Astigmatism | 6 | 2021 | 21 | 0.850 |
Why?
|
| Cross-Linking Reagents | 7 | 2023 | 51 | 0.810 |
Why?
|
| Humans | 77 | 2025 | 42163 | 0.720 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 62 | 0.680 |
Why?
|
| Keratomileusis, Laser In Situ | 3 | 2023 | 4 | 0.670 |
Why?
|
| Academies and Institutes | 1 | 2020 | 39 | 0.670 |
Why?
|
| Adult | 45 | 2025 | 13458 | 0.660 |
Why?
|
| Riboflavin | 6 | 2022 | 24 | 0.660 |
Why?
|
| Eyeglasses | 3 | 2016 | 23 | 0.660 |
Why?
|
| Male | 53 | 2025 | 22779 | 0.650 |
Why?
|
| Female | 56 | 2025 | 24018 | 0.650 |
Why?
|
| Universities | 2 | 2020 | 539 | 0.650 |
Why?
|
| Alkylating Agents | 3 | 2015 | 14 | 0.640 |
Why?
|
| Mitomycin | 3 | 2015 | 13 | 0.640 |
Why?
|
| Prospective Studies | 17 | 2022 | 1574 | 0.620 |
Why?
|
| Hyperopia | 5 | 2019 | 7 | 0.570 |
Why?
|
| Young Adult | 23 | 2025 | 4936 | 0.560 |
Why?
|
| Amblyopia | 4 | 2019 | 13 | 0.530 |
Why?
|
| Tears | 2 | 2014 | 11 | 0.510 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 234 | 0.500 |
Why?
|
| Middle Aged | 33 | 2025 | 11819 | 0.500 |
Why?
|
| Schools | 1 | 2018 | 283 | 0.500 |
Why?
|
| Endothelium, Corneal | 3 | 2020 | 8 | 0.500 |
Why?
|
| Minority Groups | 2 | 2023 | 663 | 0.500 |
Why?
|
| Aniridia | 1 | 2015 | 2 | 0.490 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 16 | 0.480 |
Why?
|
| Albinism, Oculocutaneous | 1 | 2015 | 6 | 0.480 |
Why?
|
| Prostheses and Implants | 1 | 2015 | 18 | 0.480 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 5 | 2017 | 14 | 0.480 |
Why?
|
| Photosensitizing Agents | 7 | 2023 | 55 | 0.470 |
Why?
|
| Pseudophakia | 2 | 2012 | 5 | 0.430 |
Why?
|
| Refractometry | 1 | 2014 | 16 | 0.430 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 471 | 0.420 |
Why?
|
| Child | 15 | 2022 | 3381 | 0.420 |
Why?
|
| Photography | 3 | 2011 | 48 | 0.410 |
Why?
|
| Aging | 8 | 2022 | 764 | 0.400 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 309 | 0.390 |
Why?
|
| Adolescent | 21 | 2021 | 5950 | 0.380 |
Why?
|
| Cross-Sectional Studies | 20 | 2020 | 3077 | 0.370 |
Why?
|
| Cataract Extraction | 4 | 2015 | 22 | 0.360 |
Why?
|
| Collagen | 4 | 2022 | 178 | 0.340 |
Why?
|
| Child, Preschool | 7 | 2022 | 1516 | 0.330 |
Why?
|
| Pupil | 3 | 2020 | 9 | 0.320 |
Why?
|
| Descemet Membrane | 1 | 2009 | 2 | 0.310 |
Why?
|
| Lenses, Intraocular | 1 | 2010 | 43 | 0.300 |
Why?
|
| Corneal Transplantation | 1 | 2009 | 2 | 0.300 |
Why?
|
| Follow-Up Studies | 9 | 2022 | 1051 | 0.300 |
Why?
|
| Corneal Diseases | 2 | 2024 | 11 | 0.300 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 20 | 0.300 |
Why?
|
| Prevalence | 11 | 2022 | 1597 | 0.290 |
Why?
|
| Corneal Surgery, Laser | 1 | 2007 | 1 | 0.280 |
Why?
|
| Contrast Sensitivity | 4 | 2018 | 35 | 0.280 |
Why?
|
| Biomedical Research | 2 | 2023 | 467 | 0.250 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 1058 | 0.250 |
Why?
|
| Aged | 13 | 2019 | 7982 | 0.250 |
Why?
|
| Retrospective Studies | 7 | 2019 | 2485 | 0.250 |
Why?
|
| Strabismus | 2 | 2016 | 17 | 0.250 |
Why?
|
| Students | 2 | 2023 | 617 | 0.240 |
Why?
|
| Retinoscopy | 4 | 2021 | 11 | 0.240 |
Why?
|
| Postoperative Period | 4 | 2015 | 33 | 0.240 |
Why?
|
| Sensitivity and Specificity | 2 | 2025 | 602 | 0.230 |
Why?
|
| Reference Values | 6 | 2020 | 207 | 0.230 |
Why?
|
| Anisometropia | 2 | 2021 | 3 | 0.220 |
Why?
|
| Los Angeles | 4 | 2022 | 390 | 0.220 |
Why?
|
| Dry Eye Syndromes | 2 | 2014 | 5 | 0.210 |
Why?
|
| Age Distribution | 7 | 2016 | 249 | 0.210 |
Why?
|
| Light | 2 | 2018 | 182 | 0.210 |
Why?
|
| Intraocular Pressure | 3 | 2020 | 133 | 0.200 |
Why?
|
| Corneal Dystrophy, Juvenile Epithelial of Meesmann | 1 | 2023 | 1 | 0.200 |
Why?
|
| Incidence | 4 | 2019 | 1054 | 0.200 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 94 | 0.200 |
Why?
|
| Nomograms | 1 | 2022 | 14 | 0.190 |
Why?
|
| Glare | 3 | 2017 | 4 | 0.180 |
Why?
|
| Health Status Disparities | 2 | 2022 | 705 | 0.180 |
Why?
|
| Vaccines | 1 | 2022 | 64 | 0.180 |
Why?
|
| Cohort Studies | 7 | 2022 | 1729 | 0.170 |
Why?
|
| Sex Distribution | 5 | 2016 | 224 | 0.170 |
Why?
|
| Benchmarking | 1 | 2020 | 33 | 0.170 |
Why?
|
| Government Programs | 1 | 2020 | 29 | 0.170 |
Why?
|
| Corneal Endothelial Cell Loss | 1 | 2020 | 1 | 0.170 |
Why?
|
| Basic Reproduction Number | 1 | 2020 | 2 | 0.170 |
Why?
|
| Corneal Stroma | 3 | 2018 | 6 | 0.170 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 2803 | 0.170 |
Why?
|
| Leadership | 1 | 2020 | 84 | 0.160 |
Why?
|
| Health Services Needs and Demand | 3 | 2016 | 154 | 0.160 |
Why?
|
| Eye Diseases | 1 | 2019 | 26 | 0.160 |
Why?
|
| Mothers | 1 | 2021 | 212 | 0.150 |
Why?
|
| Tonometry, Ocular | 2 | 2016 | 27 | 0.150 |
Why?
|
| Polypharmacy | 1 | 2019 | 27 | 0.150 |
Why?
|
| Physician's Role | 1 | 2019 | 39 | 0.150 |
Why?
|
| Night Vision | 1 | 2018 | 3 | 0.150 |
Why?
|
| Cultural Diversity | 1 | 2020 | 187 | 0.150 |
Why?
|
| Ultraviolet Rays | 4 | 2022 | 118 | 0.150 |
Why?
|
| Color Vision | 1 | 2018 | 10 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 81 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 86 | 0.150 |
Why?
|
| Elasticity | 2 | 2017 | 50 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2019 | 245 | 0.140 |
Why?
|
| Anterior Eye Segment | 2 | 2019 | 10 | 0.140 |
Why?
|
| Time Factors | 6 | 2019 | 1848 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2018 | 99 | 0.140 |
Why?
|
| Ultrasonics | 2 | 2007 | 15 | 0.140 |
Why?
|
| Self Medication | 1 | 2017 | 13 | 0.140 |
Why?
|
| Blindness | 1 | 2016 | 19 | 0.130 |
Why?
|
| Vision, Low | 1 | 2016 | 13 | 0.130 |
Why?
|
| Convergence, Ocular | 1 | 2016 | 3 | 0.130 |
Why?
|
| Public Health | 1 | 2021 | 405 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 174 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 573 | 0.130 |
Why?
|
| Cataract | 3 | 2015 | 51 | 0.120 |
Why?
|
| Physical Examination | 1 | 2016 | 45 | 0.120 |
Why?
|
| Eye Movements | 1 | 2015 | 16 | 0.120 |
Why?
|
| Ophthalmology | 1 | 2016 | 34 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 73 | 0.120 |
Why?
|
| Caregivers | 1 | 2017 | 195 | 0.110 |
Why?
|
| Debridement | 1 | 2014 | 4 | 0.110 |
Why?
|
| Elastic Tissue | 1 | 2014 | 9 | 0.110 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 1221 | 0.110 |
Why?
|
| Color Vision Defects | 1 | 2014 | 2 | 0.110 |
Why?
|
| Solvents | 1 | 2014 | 109 | 0.110 |
Why?
|
| Body Weights and Measures | 3 | 2009 | 25 | 0.110 |
Why?
|
| National Eye Institute (U.S.) | 1 | 2013 | 3 | 0.100 |
Why?
|
| Sickness Impact Profile | 1 | 2013 | 25 | 0.100 |
Why?
|
| Fluorophotometry | 1 | 2013 | 1 | 0.100 |
Why?
|
| Statistical Distributions | 1 | 2013 | 3 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2023 | 1586 | 0.100 |
Why?
|
| United States | 3 | 2020 | 5072 | 0.100 |
Why?
|
| Conflict of Interest | 1 | 2012 | 11 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 532 | 0.100 |
Why?
|
| Editorial Policies | 1 | 2012 | 14 | 0.100 |
Why?
|
| Bibliometrics | 1 | 2012 | 15 | 0.100 |
Why?
|
| Ultrasonography | 2 | 2011 | 132 | 0.100 |
Why?
|
| Postoperative Care | 1 | 2012 | 19 | 0.100 |
Why?
|
| Presbyopia | 1 | 2012 | 1 | 0.100 |
Why?
|
| Disclosure | 1 | 2012 | 36 | 0.100 |
Why?
|
| Double-Blind Method | 1 | 2013 | 305 | 0.100 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 51 | 0.090 |
Why?
|
| Ethanol | 1 | 2014 | 221 | 0.090 |
Why?
|
| Glaucoma | 1 | 2013 | 98 | 0.090 |
Why?
|
| Sex Factors | 5 | 2014 | 1008 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 163 | 0.090 |
Why?
|
| Aberrometry | 1 | 2010 | 1 | 0.080 |
Why?
|
| Acrylic Resins | 1 | 2010 | 12 | 0.080 |
Why?
|
| Comorbidity | 1 | 2013 | 725 | 0.080 |
Why?
|
| Fovea Centralis | 1 | 2010 | 3 | 0.080 |
Why?
|
| Menstrual Cycle | 1 | 2010 | 36 | 0.080 |
Why?
|
| Age Factors | 3 | 2019 | 1139 | 0.080 |
Why?
|
| Iris | 1 | 2009 | 26 | 0.080 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2009 | 2 | 0.080 |
Why?
|
| Automation | 1 | 2009 | 23 | 0.080 |
Why?
|
| Risk Factors | 3 | 2016 | 3942 | 0.070 |
Why?
|
| Quality of Life | 1 | 2013 | 599 | 0.070 |
Why?
|
| Contact Lenses, Hydrophilic | 1 | 2008 | 2 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2007 | 31 | 0.070 |
Why?
|
| Disease Progression | 2 | 2022 | 661 | 0.070 |
Why?
|
| Population Groups | 3 | 2013 | 59 | 0.070 |
Why?
|
| Interferometry | 1 | 2005 | 3 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2005 | 21 | 0.060 |
Why?
|
| Corneal Wavefront Aberration | 2 | 2018 | 3 | 0.060 |
Why?
|
| Qualitative Research | 2 | 2019 | 526 | 0.060 |
Why?
|
| Educational Status | 2 | 2020 | 335 | 0.060 |
Why?
|
| Entrepreneurship | 1 | 2023 | 5 | 0.050 |
Why?
|
| Mydriatics | 1 | 2022 | 6 | 0.050 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2022 | 5 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2024 | 336 | 0.050 |
Why?
|
| Urban Population | 2 | 2015 | 364 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2021 | 10 | 0.050 |
Why?
|
| ROC Curve | 1 | 2022 | 157 | 0.050 |
Why?
|
| Health Surveys | 2 | 2015 | 401 | 0.040 |
Why?
|
| Contact Tracing | 1 | 2020 | 22 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2020 | 106 | 0.040 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2019 | 1 | 0.040 |
Why?
|
| Geography | 1 | 2020 | 107 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 38 | 0.040 |
Why?
|
| Eyelid Diseases | 1 | 2019 | 5 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 332 | 0.040 |
Why?
|
| Income | 1 | 2020 | 160 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 482 | 0.040 |
Why?
|
| Linear Models | 2 | 2009 | 311 | 0.040 |
Why?
|
| Equipment Design | 1 | 2017 | 143 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 711 | 0.030 |
Why?
|
| Esotropia | 1 | 2016 | 3 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 180 | 0.030 |
Why?
|
| Vision Tests | 1 | 2015 | 6 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 222 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 638 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2014 | 3 | 0.030 |
Why?
|
| Refractive Surgical Procedures | 1 | 2014 | 1 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 9 | 0.030 |
Why?
|
| Biometry | 1 | 2014 | 50 | 0.030 |
Why?
|
| Cell Count | 1 | 2014 | 140 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 223 | 0.030 |
Why?
|
| Rose Bengal | 1 | 2013 | 3 | 0.030 |
Why?
|
| Fluorescein | 1 | 2013 | 18 | 0.030 |
Why?
|
| Dark Adaptation | 1 | 2013 | 17 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2013 | 106 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1020 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2013 | 182 | 0.020 |
Why?
|
| Rural Population | 1 | 2015 | 352 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 959 | 0.020 |
Why?
|
| Reflex, Pupillary | 1 | 2010 | 2 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2010 | 42 | 0.020 |
Why?
|
| Anisocoria | 1 | 2009 | 1 | 0.020 |
Why?
|
| Eye Color | 1 | 2009 | 3 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 162 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 123 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 916 | 0.020 |
Why?
|